KeyBanc raised the firm’s price target on Bio-Techne (TECH) to $90 from $80 and keeps an Overweight rating on the shares. Overall, fiscal Q2 represented a continuation of last quarter’s strength for Bio-Techne, and the firm believes it is a positive indicator for other life science tools companies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH: